New hope for Tough-to-Treat lung cancer
NCT ID NCT06879717
Summary
This early-stage study is testing a new three-drug combination for adults with an advanced form of lung cancer that has continued to grow despite standard treatments. The main goals are to check if the treatment is safe and to see if it can reduce certain immune cells linked to cancer. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta VZW
Roeselare, 8800, Belgium
-
Antwerp University Hospital
Antwerp, 2650, Belgium
-
Hospital Universitari Son Espases
Palma, 07120, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, 46026, Spain
-
Humanitas University, Department of Medical Oncology
Rozzano, Milan, 20072, Italy
-
Institut Català d'Oncologia Hospitalet
Barcelona, 08908, Spain
-
Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"
Meldola, Forlì-Cesena, 47014, Italy
Conditions
Explore the condition pages connected to this study.